 |
| Ligand ID: LEI Drugbank ID: DB00859(Penicillamine) Indication:For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis. |
| DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
|---|---|---|---|---|---|---|---|---|---|---|
 Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 1q2w | 3C-LIKE PROTEASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.65A | 6.56 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 1ssk | NUCLEOCAPSID PROTEIN (SARSr-CoV) | 4 / 5 | LEU A 34GLN A 138LEU A 139GLU A 152 | 1.60A | 9.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 1wnc | E2 GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | LEU E 927LYS F 929GLN F 931LEU F 930 | 1.36A | 19.72 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 1wnc | E2 GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | GLN E1161LEU E 927LYS D 929LEU D 930 | 1.46A | 19.72 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 1z1i | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.41A | 6.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 1zv7 | SPIKE GLYCOPROTEIN (SARS-COVFRA) | 4 / 5 | LEU A 19GLN A 13LEU B 26GLU A 15 | 1.76A | 21.05 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 1zv8 | E2 GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | LYS I 29GLN I 31LEU I 30LEU K 30 | 1.47A | 18.00 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 1zv8 | E2 GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | LEU G 30LYS I 29GLN I 36LEU I 30 | 1.63A | 18.00 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2beq | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | LYS C 929GLN C 936LEU C 930LEU B 930 | 1.53A | 27.50 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2beq | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | LYS D1187GLN D1190LEU D1185GLU D1189 | 1.73A | 20.83 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2beq | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | LEU B 930LYS C 929GLN C 936LEU C 930 | 1.63A | 27.50 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2beq | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | LEU D1182GLN F1183LEU F1185GLU F1184 | 1.54A | 20.83 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2cjr | NUCLEOCAPSID PROTEIN (SARS-COVTW1) | 4 / 6 | LYS C 348GLN C 346LEU C 340LEU C 354 | 1.60A | 10.16 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2cme | HYPOTHETICAL PROTEIN5 (SARSr-CoV) | 4 / 6 | LYS C 41GLN C 21LEU C 22LEU D 22 | 1.72A | 16.67 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2cme | HYPOTHETICAL PROTEIN5 (SARSr-CoV) | 4 / 6 | LYS G 41GLN G 21LEU G 22LEU H 22 | 1.74A | 17.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2fxp | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | LYS A 25GLN A 24GLU B 26LEU B 30 | 1.69A | 24.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2jzf | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 4 / 6 | LYS A 628LEU A 596GLU A 601LEU A 603 | 1.67A | 14.95 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2op9 | REPLICASEPOLYPROTEIN 1AB(PP1AB, ORF1AB)3C-LIKE PROTEINASE(3CL-PRO, 3CLP) (SARSr-CoV) | 4 / 5 | LEU B 271GLN B 273LEU B 268GLU B 270 | 1.57A | 6.86 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2q6g | REPLICASEPOLYPROTEIN 1AB (SARS-COVBJ01) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.59A | 6.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2qiq | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.58A | 5.80 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2vj1 | MAIN PROTEINASE (SARSr-CoV) | 4 / 5 | LEU B 271GLN B 273LEU B 268GLU B 270 | 1.63A | 6.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | LYS A 277LEU A 275LYS A 216LEU A 212 | 1.59A | 7.17 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 5 | LEU A 85LYS A 46GLN A 52LEU A 50 | 1.78A | 7.17 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 2xyv | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | LEU A 275GLU A 276LYS A 214LEU A 212 | 1.66A | 7.17 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 2xyv | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 5 | LEU A 85LYS A 46GLN A 52LEU A 50 | 1.79A | 7.17 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 3bgf | F26G19 FAB (Musmusculus) | 4 / 6 | GLN C 37LEU C 36GLU C 38LEU B 45 | 1.38A | 13.95 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3bgf | F26G19 FAB (Musmusculus) | 4 / 5 | LEU B 45GLN C 37LEU C 36GLU C 38 | 1.28A | 8.50 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3d0g | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 5 | LEU A 91GLN A 388LEU A 95GLU A 564 | 1.49A | 4.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 3d0i | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 6 | GLN A 98LEU A 391LYS A 562LEU A 392 | 1.32A | 4.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3d62 | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.64A | 5.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3ea8 | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.58A | 6.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3eaj | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.63A | 6.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 3i6g | HLA, A-2 (Homosapiens) | 4 / 6 | LYS D 127GLN D 115LEU D 130LEU D 156 | 1.45A | 10.23 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 6 | GLN C 273LEU C 268GLU C 270LEU C 271 | 1.57A | 6.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3m3s | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.69A | 6.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3m3t | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.41A | 6.56 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3m3v | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU B 271GLN B 273LEU B 268GLU B 270 | 1.48A | 6.23 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 3mj5 | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 4 / 6 | LYS A 298GLN A 255LEU A 254LEU A 283 | 1.55A | 8.00 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 6 | GLN A 98LEU A 391LYS A 562LEU A 392 | 1.41A | 3.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 5 | LEU B 91GLN B 388LEU B 95GLU B 564 | 1.76A | 3.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 3sna | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.66A | 6.88 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 4hi3 | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU B 271GLN B 273LEU B 268GLU B 270 | 1.56A | 6.73 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 4m0w | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 4 / 6 | LYS A 298GLN A 255LEU A 254LEU A 283 | 1.74A | 7.41 | NoneNoneGOL A 406 (-4.7A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 4mds | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU A 271GLN A 273LEU A 268GLU A 270 | 1.59A | 6.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 4tww | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU B 271GLN B 273LEU B 268GLU B 270 | 1.46A | 6.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 5b6o | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 5 | LEU B 271GLN B 273LEU B 268GLU B 270 | 1.50A | 6.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 5tl6 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 4 / 6 | LYS D 298GLN D 255LEU D 254LEU D 283 | 1.69A | 7.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 4 / 5 | LEU C 804GLN C 786LEU C 803GLU C 801 | 1.70A | 2.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 5zvm | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | LYS A 929GLN A 931LEU A 930LEU B 930 | 1.74A | 17.50 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 5zvm | PAN-COV INHIBITORYPEPTIDE EK1SPIKE GLYCOPROTEIN (SARSr-CoV;syntheticconstruct) | 4 / 5 | LEU B 930LYS C 929GLN C 931LEU b 16 | 1.70A | 17.50 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6acj | ACE2 (Homosapiens) | 4 / 6 | LYS D 74GLN D 76LEU D 73LEU D 391 | 1.34A | 3.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6acj | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | LEU A 286GLN A 280LEU A 283GLU A 285 | 1.76A | 2.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6acj | ACE2 (Homosapiens) | 4 / 5 | LEU D 391LYS D 74GLN D 76LEU D 73 | 1.65A | 3.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 5 | LEU C 804LYS C 929GLN C 931LEU C 930 | 1.63A | 2.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6cs2 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 6 | LYS B 946LEU B 944LYS B 818LEU B 840 | 1.58A | 2.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6iex | MHC CLASS I ANTIGEN (Homosapiens;SARSr-CoV) | 4 / 5 | LEU C 9GLN A 72LEU C 7GLU A 76 | 1.71A | 29.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6iex | MHC CLASS I ANTIGEN (Homosapiens) | 4 / 5 | LEU A 172LYS A 178LEU A 179GLU A 180 | 1.52A | 7.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6iex | MHC CLASS I ANTIGEN (Homosapiens;SARSr-CoV) | 4 / 6 | GLN A 72LEU C 7GLU A 76LEU C 9 | 1.58A | 7.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6m17 | ACE2 (Homosapiens) | 4 / 6 | GLN B 429GLU B 430LYS B 419LEU B 424 | 1.59A | 4.28 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6m18 | ACE2 (Homosapiens) | 4 / 5 | LEU B 91GLN B 388LEU B 95GLU B 564 | 1.56A | 4.28 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6nb7 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | LYS A 946LEU A 944LYS A 818LEU A 840 | 1.73A | 2.45 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_B_LEIB16_0 (COIL SER L16D-PEN) | 6nus | NSP12 (SARSr-CoV) | 4 / 5 | LEU A 638LYS A 574GLN A 573LEU A 575 | 1.36A | 2.34 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6nus | NSP12 (SARSr-CoV) | 4 / 6 | LYS A 574GLN A 573LEU A 575LEU A 638 | 1.32A | 2.34 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3H5G_A_LEIA16_0 (COIL SER L16D-PEN) | 6vw1 | ACE2 (Homosapiens) | 4 / 6 | GLN A 98LEU A 391LYS A 562LEU A 392 | 1.39A | 4.49 | None |